Setipiprant clinical trials
Also written ACT-129968.
How each study uses setipiprant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2011 | 3 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
ACT-453859 (1)
Studies
Open first, then newest update. How each study uses setipiprant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Study of ACT-129968 in Adult Patients With Seasonal Allergic RhinitisCompletedPhase 2Idorsia Pharmaceuticals Ltd.NCT01241214Written as ACT-129968
- A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in MalesCompletedPhase 2AllerganNCT02781311Written as Setipiprant
- Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic RhinitisCompletedPhase 3Idorsia Pharmaceuticals Ltd.NCT01484119Written as ACT-129968
- Clinical Study to Assess the Pharmacokinetics, Safety, and Tolerability of ACT-129968 in Healthy SubjectsCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT01877629Written as ACT-129968 500 mg tablet
- A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)CompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT02381496Written as Setipiprant 500 mg
- Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled AsthmaCompletedPhase 2Idorsia Pharmaceuticals Ltd.NCT01225315Written as Setipiprant
Codes
What other systems call setipiprant · ClinicalTrials.gg INT006340
- UNII (FDA) BHF20LA2GMSETIPIPRANTConfirmed FDA, Wikidata
- Wikidata Q21098972setipiprantConfirmed FDA, Wikidata
- NCI Thesaurus C152348SetipiprantOne source FDA
- DrugBank DB12562One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | BHF20LA2GM | SETIPIPRANT | Confirmed FDA, Wikidata |
| Wikidata | Q21098972 | setipiprant | Confirmed FDA, Wikidata |
| NCI Thesaurus | C152348 | Setipiprant | One source FDA |
| DrugBank | DB12562 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.